NEW YORK (GenomeWeb News) – Sequenom today said that it has launched a certified service program for its MassArray System and has named the first laboratory participants.
NewGene has launched a sequencing-based test on Roche's 454 GS FLX for Noonan syndrome and other related disorders.
NewGene's hereditary breast cancer test
NewGene is initially targeting the UK market and patients with an increased hereditary risk for breast cancer for its pyrosequencing-based assay.
The UK firm will provide services for NimbleGen Sequence Capture Arrays with sequencing on Roche 454's Genome Sequencer FLX System.
The company expects to use Roche's 454 technology to offer full-gene sequencing tests at a lower cost and faster turnaround time than existing providers using Sanger sequencing.
David Huntley, Ann Curtis, Jonathan Robinson, Jonathan Coxhead, David Allison, John Burn, Michael Wright, Kary Mullis
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.